• Grace Therapeutics highlighted GTx-104, an intravenous nimodipine candidate for aneurysmal subarachnoid hemorrhage, positioning it as a potential alternative to oral nimodipine.
• Phase 3 STRIVE-ON safety trial met its primary endpoint, showing 28% clinically significant hypotension with GTx-104 versus 35% with oral capsules.
• Trial data showed 54% of GTx-104 patients received at least 95% of prescribed dose intensity versus 8% for oral capsules.
• 90-day outcomes showed a 29% relative increase in good recovery versus oral capsules; trial was not powered for statistical comparisons.
• FDA issued a Complete Response Letter in April 2026 citing CMC and manufacturing readiness; no clinical deficiencies identified; company plans an NDA resubmission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein.